Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Historical Control In Psoriatic Arthritis May Hinge On Background Therapy

Aug 18 2017

• By Derrick Gingery

FDA entrance sign 2016

Related Content

Pfizer's Xeljanz Gains FDA Panel Nod In Psoriatic Arthritis, But Labeling Questions Remain

Aug 03 2017

Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?

Aug 02 2017

Could FDA Force Pfizer To Push Shingles Vaccination With Xeljanz Psoriatic Arthritis Approval?

Aug 18 2017

User Fee Goal Dates

Feb 07 2017

Related Companies

Pfizer Inc.

AbbVie Inc.

Additional Topics

United States Biologics Clinical Trials Regulation FDA Advisory Committees BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window